Dynamics and control of the global tuberculosis epidemic

Studies of disease burden have reaffirmed that tuberculosis is among the top 10 causes of death in the world. The tuberculosis epidemic in most countries could eventually be brought under control by implementing the World Health Organization’s (WHO) directly observed therapy, short course (DOTS) strategy, although tuberculosis linked to human immunodeficiency virus (HIV) in Africa and multidrug-resistant tuberculosis (MDR-TB) in the former Soviet Union urgently demand adaptations and extensions of DOTS. Most high-incidence countries have achieved treatment success rates approaching the WHO 85% target in pilot projects. In the long term, we may have better diagnostics, drugs, and vaccines to control the disease; for the next 5 years, the central problem in global tuberculosis control is to expand DOTS coverage in high-incidence countries. Improved case finding and diagnosis, coupled with best-practice short-course chemotherapy, could quickly and dramatically cut the number of years of healthy life lost due to tuberculosis, especially by preventing death.

[1]  E. Vynnycky,et al.  Influence of sampling on estimates of clustering and recent transmission of Mycobacterium tuberculosis derived from DNA fingerprinting techniques. , 1999, American journal of epidemiology.

[2]  C. Dye,et al.  Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. , 1999, JAMA.

[3]  I. Onorato,et al.  Extensive transmission of Mycobacterium tuberculosis from a child. , 1999, The New England journal of medicine.

[4]  Alimuddin Zumla,et al.  A study of maternal mortality at the University Teaching Hospital, Lusaka, Zambia: the emergence of tuberculosis as a major non-obstetric cause of maternal death. , 1999, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[5]  Grosset Pj.  Systematic drug susceptibility testing: a necessary component of the 'DOTS plus' strategy? , 1999 .

[6]  E. Nardell,et al.  Management of MDR-TB in resource-poor countries. , 1999, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[7]  G. Cangelosi,et al.  Drug susceptibility testing of Mycobacterium tuberculosis: a neglected problem at the turn of the century. , 1999, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[8]  C. Macintyre,et al.  Longitudinal incidence of tuberculosis in South-East Asian refugees after re-settlement. , 1999, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[9]  P D van Helden,et al.  Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment. , 1999, The New England journal of medicine.

[10]  E. Telzak.  Treatment outcome of multidrug-resistant tuberculosis , 2000 .

[11]  Jim Y. Kim,et al.  Community based approaches to the control of multidrug resistant tuberculosis: introducing “DOTS-plus” , 1998, BMJ.

[12]  C. Dye,et al.  Progress in global tuberculosis control 1995-1996, with emphasis on 22 high-incidence countries. Global Monitoring and Surveillance Project. , 1999, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[13]  P E Fine,et al.  The long-term dynamics of tuberculosis and other diseases with long serial intervals: implications of and for changing reproduction numbers , 1998, Epidemiology and Infection.

[14]  M. Behr,et al.  Transmission of Mycobacterium tuberculosis from patients smear-negative for acid-fast bacilli , 1999, The Lancet.

[15]  I. Onorato,et al.  Tuberculosis and race/ethnicity in the United States: impact of socioeconomic status. , 1998, American journal of respiratory and critical care medicine.

[16]  Christopher Dye,et al.  Prospects for worldwide tuberculosis control under the WHO DOTS strategy , 1998, The Lancet.

[17]  A. Williams,et al.  Calculating the global burden of disease: time for a strategic reappraisal? , 1999, Health economics.

[18]  P E Fine,et al.  Interpreting the decline in tuberculosis: the role of secular trends in effective contact. , 1999, International journal of epidemiology.

[19]  E. Salpeter,et al.  Mathematical model for the epidemiology of tuberculosis, with estimates of the reproductive number and infection-delay function. , 1998, American journal of epidemiology.

[20]  V. Wiseman,et al.  Burden of illness estimates for priority setting: a debate revisited. , 1998, Health policy.

[21]  Punga,et al.  Primary multidrug-resistant tuberculosis--Ivanovo Oblast, Russia, 1999. , 1999, MMWR. Morbidity and mortality weekly report.

[22]  G Bentham,et al.  Tuberculosis mortality in England and Wales during 1982-1992: its association with poverty, ethnicity and AIDS. , 1998, Social science & medicine.

[23]  C. Dye,et al.  Rational 'DOTS plus' for the control of MDR-TB. , 1999, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[24]  R. Anderson.  Tuberculosis: old problems and new approaches. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[25]  H L Rieder,et al.  Global surveillance for antituberculosis-drug resistance, 1994-1997. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. , 1998, The New England journal of medicine.

[26]  N. Nagelkerke,et al.  Mortality among tuberculosis patients in The Netherlands in the period 1993-1995. , 1998, The European respiratory journal.

[27]  Merrick Zwarenstein,et al.  Randomised controlled trial of self-supervised and directly observed treatment of tuberculosis , 1998, The Lancet.

[28]  C. Dye,et al.  A cost-benefit analysis of BCG revaccination in the Czech Republic. , 1999, Vaccine.

[29]  R. Coninx,et al.  First-line tuberculosis therapy and drug-resistant Mycobacterium tuberculosis in prisons , 1999, The Lancet.

[30]  F. Portaels,et al.  Inadequacy of the current WHO re-treatment regimen in a central Siberian prison: treatment failure and MDR-TB. , 1999, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[31]  Fifteen year follow up of trial of BCG vaccines in south India for tuberculosis prevention. Tuberculosis Research Centre (ICMR), Chennai. , 1999, The Indian journal of medical research.

[32]  J A Romeyn,et al.  Exogenous reinfection in tuberculosis. , 1970, The American review of respiratory disease.

[33]  C. Murray,et al.  Modeling the impact of global tuberculosis control strategies. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[34]  Christopher Dye,et al.  Global Burden of Tuberculosis: Estimated Incidence, Prevalence, and Mortality by Country , 1999 .